A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 Following Intrathecal Administration in Participants With Early Symptomatic Alzheimer's Disease
Latest Information Update: 05 Dec 2025
At a glance
- Drugs RO 7812653 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
Most Recent Events
- 26 Nov 2025 New trial record